Wegovy coverage by insurance varies widely in 2026 depending on your plan type, employer, and state. Many commercial insurance plans now cover Wegovy when prescribed for obesity or a related condition, but Medicare coverage under Part D remains restricted to plans that have opted in, and Medicaid coverage differs by state. Your out-of-pocket cost can range from as little as $0 with full coverage to over $1,300 per month without it.
How Does Commercial Insurance Handle Wegovy in 2026?
Private and employer-sponsored health plans make their own formulary decisions each year. As of 2026, coverage is more common than it was at Wegovy's 2021 launch, but it is far from universal. According to a KFF Health Policy analysis, roughly half of large employers covered at least one GLP-1 medication for weight loss by late 2024, and that share has continued to grow into 2026 as employer interest in cardiometabolic benefits has increased.
Commercial plans that do cover Wegovy typically require:
- A diagnosis of obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition such as type 2 diabetes, hypertension, or high cholesterol — consistent with FDA-approved indications in the Wegovy label
- Documentation that lifestyle interventions have been attempted
- Prior authorization from your doctor
- Step therapy (trying a lower-cost medication first, in some cases)
Tier placement on your formulary determines your copay. Wegovy is most often placed on a specialty tier, which can mean 25–33% coinsurance rather than a flat copay.
Does Medicare Cover Wegovy in 2026?
This is where the policy landscape shifted meaningfully. The Inflation Reduction Act of 2022 did not immediately open Medicare Part D to obesity medications, but subsequent CMS rulemaking expanded Part D plan options. Starting in 2026, certain Medicare Part D plans may voluntarily cover anti-obesity medications including Wegovy, particularly for enrollees who have a cardiovascular risk indication — following the 2023 FDA label update that added reduction of cardiovascular events as an approved use.
Key points for Medicare beneficiaries:
- Part D plans are not required to cover Wegovy — coverage depends on whether your specific plan has added it to its formulary.
- Enrollees with a cardiovascular disease diagnosis have the strongest coverage case under the expanded indication.
- The CMS Drug Price Negotiation Program has placed semaglutide products on its negotiation shortlist, which could reduce list prices further in coming years.
- Medicare Part B does not cover Wegovy.
Call your Part D plan directly or use the Medicare Plan Finder at medicare.gov to confirm whether Wegovy is on your 2026 formulary before assuming coverage.
What About Medicaid?
Medicaid coverage is determined state by state. As of 2025–2026, fewer than half of state Medicaid programs covered GLP-1 medications specifically for weight loss, according to KFF tracking data. However, states that have expanded coverage often require prior authorization and restrict use to adults meeting BMI thresholds with documented comorbidities. Contact your state Medicaid office or managed care plan to verify current policy, as formularies update annually.
Most important takeaway: Even if your plan type generally covers Wegovy, approval is not automatic. Prior authorization is almost universally required, and a denial is not final — you have the right to appeal, and your prescriber can submit a letter of medical necessity that significantly improves approval odds.
What Does the Coverage Timeline Look Like After You Start the Process?
| Week / Step | What Happens | Your Action |
|---|---|---|
| Week 1–2 | Prescriber submits prior authorization (PA) request with clinical documentation | Confirm your prescriber has your full diagnosis and BMI on record |
| Week 2–3 | Insurance reviews PA; may request additional records | Respond quickly to any insurer requests; ask prescriber to call if needed |
| Week 3–4 | Approval or denial issued | If approved, fill prescription. If denied, request denial reason in writing. |
| Week 4–6 | First-level appeal (if denied) | Prescriber submits letter of medical necessity; you file formal appeal |
| Week 6–10 | External review or second-level appeal | Request independent external review if internal appeal is also denied |
| Ongoing | Annual formulary renewal | Reconfirm coverage at each plan year change; resubmit PA if required |
What If Insurance Won't Cover Wegovy?
If you are uninsured, underinsured, or denied coverage, several options may reduce your cost:
- Novo Nordisk Patient Assistance Program: The manufacturer offers NovoCare assistance for qualifying patients. Visit novonordisk-us.com for income-based eligibility details.
- Wegovy Savings Card: Commercially insured patients who meet income criteria may pay as little as $25 per month through Novo Nordisk's savings program (terms subject to change; not valid for federal program beneficiaries).
- Telehealth weight-loss platforms: Some platforms negotiate cash-pay pricing, though costs remain substantially higher than insured rates.
- Appealing a denial: The STEP 1 trial published in NEJM (Wilding et al., 2021) demonstrated a mean 14.9% body weight reduction with semaglutide 2.4 mg, data your prescriber can cite in a medical necessity letter.
Frequently Asked Questions
Insurance coverage for Wegovy in 2026 is improving but remains inconsistent across plan types and states. Before filling your first prescription, call your insurer, confirm your plan's formulary, and work with your prescriber on prior authorization. If you are denied, an appeal supported by strong clinical documentation is worth pursuing — approval rates after appeal can be significant.
- FDA prescribing information for Wegovy (semaglutide) injection, 2021, updated 2023
- Inflation Reduction Act of 2022, Public Law 117-169
- CMS Medicare Part D coverage guidance for obesity medications, 2024
- TREAT and STEP trials: Wilding JPH et al., NEJM 2021; DOI:10.1056/NEJMoa2032183
- KFF Health Policy Report: Coverage of GLP-1 Drugs for Weight Loss, 2024
- CMS Final Rule: Medicare Drug Price Negotiation Program, 2024